Market revenue in 2023 | USD 188.3 million |
Market revenue in 2030 | USD 309.4 million |
Growth rate | 7.4% (CAGR from 2023 to 2030) |
Largest segment | Targeted therapy |
Fastest growing segment | Immunotherapy |
Historical data covered | 2018 - 2022 |
Base year for estimation | 2023 |
Forecast period covered | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Chemotherapy, Immunotherapy, Targeted Therapy, Hormonal Therapy |
Key market players worldwide | Novartis AG ADR, Pfizer Inc, Merck KGaA, Janssen Pharmaceuticals, Celgene, Roche Holding AG, AstraZeneca PLC, AbbVie Inc, Bristol-Myers Squibb Co, Macrogenics Inc, Celldex Therapeutics Inc, Sanofi SA, Amgen Inc |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to breast cancer drugs will help companies and investors design strategic landscapes.
Targeted therapy was the largest segment with a revenue share of 64.26% in 2023. Horizon Databook has segmented the Middle East & Africa breast cancer drugs based on chemotherapy, immunotherapy, targeted therapy, hormonal therapy covering the revenue growth of each sub-segment from 2018 to 2030.
Rising demand for effective and cost-efficient cancer therapies is one of the major factors contributing to the growth of the breast cancer drugs market in the MEA region. Factors such as increase in the need for improved healthcare infrastructure and high burden of diseases, such as cancer, are expected to boost the demand for advanced treatment strategies.
Increasing awareness pertaining to breast cancer is expected to boost market growth. According to the UAE health guidelines, all women aged 30 to 40 years should get a clinical breast examination done once in every 3 years and women over 20 years should be “breast aware.”
Horizon Databook provides a detailed overview of continent-level data and insights on the Middle East & Africa breast cancer drugs, including forecasts for subscribers. This continent databook contains high-level insights into Middle East & Africa breast cancer drugs from 2018 to 2030, including revenue numbers, major trends, and company profiles.
No related regions found.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account